Table.
Baseline characteristics of HIV-infected, opioid-dependent participants enrolled in a randomized trial comparing clinic-based BUP to referred-treatment
| Characteristic | Referred-treatment (n=47) |
Clinic-based BUP (n=46) |
|---|---|---|
| Female, n (%) | 12 (26) | 14 (30) |
| African American, n (%) | 47 (100) | 44 (96) |
| Age, years, median (IQR) | 46 (42–52) | 45 (42–50) |
| High school graduate or equivalent, n (%) | 22 (48) | 27 (59) |
| Housing status, n (%) | ||
| Own or rent home | 18 (38) | 27 (59) |
| Stay with family/friends | 22 (47) | 14 (30) |
| Group home | 2 (4) | 2 (4) |
| Homeless, shelter, or single room occupancy | 5 (11) | 3 (7) |
| Employed, n (%) | 15 (32) | 13 (28) |
| Depression scorea, median (IQR) | 9 (6–13) | 10 (6–14) |
| Incarcerated ≥ 3 days in lifetime, n (%) | 37 (79) | 35 (76) |
| Type of opioid used in prior month, n (%) | ||
| Heroin | 47 (100) | 42 (91) |
| Prescription opioid | 12 (26) | 13 (28) |
| Days opioid used in prior month, median (IQR) | 30 (20–30) | 30 (20–30) |
| Used cocaine in prior month, n (%) | 37 (79) | 30 (65) |
| Days usedb, median (IQR) | 10 (5–30) | 15 (4–25) |
| Used alcohol in prior month, n (%) | 28 (60) | 22 (48) |
| Days usedb, median (IQR) | 8 (3–15) | 9 (4–15) |
| Injected drugs in prior month, n (%) | 36 (77) | 20 (43)c |
| Years of opioid use, median (IQR) | 20 (14–26) | 18 (10–25) |
| Hospitalized in prior 3 months, n (%) | 11 (23) | 15 (33) |
| AIDS-defining opportunistic condition in prior 3 months, n (%) | 3 (7) | 6 (13) |
| Hepatitis C antibody positive,d n (%) | 38 (86) | 30 (67)e |
| Taking antiretroviral therapy, n (%) | 24 (51) | 25 (54) |
| Nadir CD4 count, cells × 109/L, median (IQR) | 206 (40–351) | 110 (12–232)f |
| Current CD4 count, cells × 109/L, median (IQR) | 304 (177–482) | 228 (68–397) |
| HIV RNA < 400 copies/mL, n (%) | 19 (40) | 19 (41) |
| HIV RNA log10 copies/mL in subjects with HIV RNA > 400 copies/mL, median (IQR) | 4.6 (3.0–5.0) | 4.4 (3.9–5.1) |
BUP, buprenorphine/naloxone; IQR, interquartile range
a
CES-D 10-item survey addressing symptoms in previous week, higher scores correspond to more severe depressive symptoms (12).
b
Days of substance use in prior month among those reporting any use.
c
P=0.001 compared to referred-treatment arm
d
Hepatitis C status unknown for 4 subjects.
e
P=0.045 compared to referred-treatment arm.
f
P=0.089 compared to referred-treatment arm.